Eli Lil­ly’s Moun­jaro peak sales could now top $68B – an­a­lyst; Elon Musk’s brain-chip com­pa­ny reels in $280M

A few months ago, BMO Cap­i­tal an­a­lyst Evan Seiger­man es­ti­mat­ed Eli Lil­ly’s type 2 di­a­betes drug Moun­jaro would have more than $50 bil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.